The collaboration with Regeneron for nex-z is a boost for Intellia as it provides the latter with resources to support the development of the candidate. NTLA's Another Candidate NTLA-2002 & Other Developments Intellia Therapeutics, Inc. (NTLA) is developing its lead CRISPR-based, in vivo genome-editing candidate, nexiguran ziclumeran (nex-z, formerly known as NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis. Intellia has collaborated with Regeneron Pharmaceuticals (REGN) for the development ...

NEW YORK, March 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). Shareholders who purchased shares of NTLA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/intellia-therapeutics-inc-loss-submission-form/?id=139401&from=4 CLASS PE ...

NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

NEW YORK, March 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/intellia-therapeutics ...

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding the viability and development of its gene editing therapy NTLA-3001, leading to significant stock price declines [4][5]. Company Overview - Intellia Therapeutics is a genome editing company focused on developing curative therapeutics [3]. Class Action Details - The class action lawsuit represents investors who purchased Intellia securities between July 30, 2024, and January 8, 2025, with a deadline for filing a lead plaintiff motion set for April 14, 2025 [1]. - The lawsuit alleges that Intellia's management made false statements about the reliability of NTLA-3001's development and failed to disclose critical information about the program's viability [4]. Allegations Against Intellia - The lawsuit claims that Intellia misrepresented the timelines and feasibility of NTLA-3001, asserting that the viral-based editing methods were costly and inefficient compared to non-viral alternatives [4]. - It is alleged that Intellia was not prepared to dose patients with NTLA-3001 or maintain its research and development efforts effectively [4]. - Following a company reorganization announcement on January 9, 2025, which included the discontinuation of NTLA-3001, Intellia's stock price dropped by over 15% [5].

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/intellia-therap ...

Intellia Therapeutics (NTLA) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational in vivo genome-editing candidate, Nexiguran ziclumeran (nex-z, also known as NTLA-2001), for a new indication.The regulatory body has now granted the RMAT designation to nex-z for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM).The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well ...

NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2024 lead plaintiff deadline. SO WHAT: If you purchased Intellia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Intellia Therapeutics, Inc. (NASDAQ: NTLA) securities between June 30, 2024 and January 28, 2025. Intellia describes itself as a leading clinical-stage gene editing company, focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. For more information, submit a form, email attorney Aaron Dumas, Jr., o ...

CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to nexiguran ziclumeran (nex-z, also known as NTLA-2001) for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM). "This is a meaningful step f ...